[1］Spencer CM,Noble S. Rivastigmine.a review of its use in Alzheimer's disease［J］. Drugs Aging ,1998,13(5):391. [2］Jann MW. Pharmacology and clinical efficacy of cholinesterase inhibitors［J］. Am J Health-Syst Pharm ,1998, 55(Suppl 2):S22. [3］Jann MW.Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease［J］. Pharmacotherapy ,2000,20(1):1. [4］Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease［J］. Clin Ther ,1998, 20(4): 634. [5］.Enz A, Boddeke H, Gray J， et al .Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor［J］. Ann NY Acad Sci ,1991,640:272. [6］Sramek JJ, Anand R, Wardle TS, et al. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease［J］. Life Sci ，1996，58:1201. [7］Enz A, Amstutz R, Boddeke H， et al .Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res ,1993, 98:431